6 reports

The data were presented at the European Academy of Allergy and Clinical Immunology ##th Annual Congress 2016.

  • Antifungal
  • Health Services
  • Pharmaceutical
  • World
  • Sensorion S.A.

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Digestive System Disorder
  • Health Services
  • Monoclonal Antibody
  • United States

IT WAS ALSO UNDER DEVELOPMENT FORAUTOIMMUNE DISEASES AND ALLERGIES.

  • Dermatology
  • Health Services
  • United States
  • World
  • Product Initiative

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • Digestive System Disorder
  • Eye Disease
  • Health Services
  • United States

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Allergy Drug
  • Digestive System Disorder
  • Health Services
  • United States
  • Product Initiative

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Antifungal
  • Digestive System Disorder
  • Health Services
  • Respiratory Disease
  • AstraZeneca PLC